Human testing of oral PMPA for treatment of HIV begins
Tags: ANTIVIRAL agents
Related Articles
- EFAVIRENZ COMBINATION POTENT AFTER 48 WEEKS. // AIDS Patient Care & STDs;Feb1998, Vol. 12 Issue 2, p145
Reports that according to a study, the combination of the antiviral drug, efavirenz (Sustiva) and indinavir (Crixivan) can be potent after 48 weeks. Number of participants in the study; Reported side effects of patients who took efavirenz.
- EARLY RESULTS FROM SPICE STUDY REPORTED. // AIDS Patient Care & STDs;Feb1998, Vol. 12 Issue 2, p145
Announces that the SPICE study reported that nelfinavir + saquinavir + two nucleoside analog RTIs of choice, a four-drug antiviral combination, was found to be better that any other combination studied. Most common adverse side effect of the combination drug; Information on the final results of...
- RITONAVIR/INDINAVIR COMBINATION STUDY SHOWS PROMISING DOSING RESULTS. // AIDS Patient Care & STDs;Feb1998, Vol. 12 Issue 2, p146
Presents information from a study which looked at four combinations of ritonavir and indinavir. Reason reduced doses of the drugs were evaluated; What the combination of ritonavir and indinavir resulted in; What results of the study suggested.
- WIDER DISTRIBUTION FOR ABACAVIR. // AIDS Patient Care & STDs;Jun98, Vol. 12 Issue 6, p493
Reports that the access program for the drug abacavir has been broaden to include more patients who can qualify to take the antiviral. How this program differs from other programs; What is the criteria which patients have to pass.
- Antiviral drug resistance. Pillay, Deenan; Zambon, Maria // BMJ: British Medical Journal (International Edition);09/05/98, Vol. 317 Issue 7159, p660
Presents information on the development of effective antiviral drugs. Biological basis of antibiotic resistance; Measure of drug resistance through specialized laboratories; Information on the drugs used to treat herpes and influenza. INSET: Summary points.
- A looking-glass war on viruses. Eastwood, Gary // New Scientist;9/14/96, Vol. 151 Issue 2047, p20
Reports that German chemists have improved a class of drugs that could sabotage viruses or cancer cells by forming mirror images of the building blocks of nature. Drugs based on chains of nucleotides; Creation of mirror-image copies of RNA-based oligonucleotides; Use of arginine as template.
- Oseltamivir-resistant 2009 H1 N1 increased among immunocompromised patients. // Infectious Disease News;Sep2011, Vol. 24 Issue 9, p25
The article offers a perspective on a research study which indicated the increased emergence of oseltamivir-resistant 2009 H1N1 in England and Scotland, particularly among immunocompromised patients.
- Nevirapine approved. // AIDS Patient Care & STDs;Dec96, Vol. 10 Issue 6, p378
Reports on the approval of the antiviral drug called nevirapine (Viramune) by the Food and Drug Administration. Use of combinatory therapy on adults.
- DMP 266 and indinavir combination. // AIDS Patient Care & STDs;Aug97, Vol. 11 Issue 4, p287
Focuses on the study conducted by DuPont Merck's DMP 266 and Crixivan (indinavir), focusing on antiviral drugs. Methodology used in the study; Participants in the study; Circumstances surrounding the study; Conclusions reached.
- NDA submitted for new formulation of saquinavir. // AIDS Patient Care & STDs;Aug97, Vol. 11 Issue 4, p288
Reports on the submission made by Hoffmann-La Roche Incorporated for a formulation of the drug saquinavir mesylate as it relates to antiviral agents. Description of the formulation required; Benefits of using the drug; Information suggesting that marketing clearance be requested for soft...
